Effect of bempedoic acid on cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease
Liver steatosis and fibrosis assessed with non-invasive tests are associated with an increased risk of MACE4. Bempedoic acid reduced MACE4 risk, with an additional benefit in patients with elevated steatosis scores.
Authors
- Vivian de Jong (ORCID: https://orcid.org/0000-0002-4692-479X)
- LeAnne T. Bloedon
- William J. Sasiela (ORCID: https://orcid.org/0000-0002-1284-3385)
- S J Nicholls
- S E Nissen
- M C Cabezas
- Diederick E Grobbee
- A Michael Lincoff
- Michael Li
Institutions
- Cleveland Clinic (US)
- Esperion Therapeutics (United States) (US)
- Erasmus MC (NL)
- University Medical Center Utrecht (NL)
- Sint Franciscus Gasthuis (NL)
- Monash University (AU)
- Erasmus University Rotterdam (NL)
Publication Details
- Journal
- European Journal of Preventive Cardiology
- Published
- 2026-02-13
- DOI
- https://doi.org/10.1093/eurjpc/zwag102
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00